Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

nal Formulary, which is a list of products generally covered under VA pharmacy benefits.
  • On March 4, 2013, the company entered into an agreement with Laboratorios Grifols, S.A., for the development, manufacture and supply of commercial quantities of OFIRMEV in flexible plastic bags. Cadence plans to submit a supplemental NDA to the FDA in the second half of 2013 seeking approval of the product to be manufactured by Grifols.
  • In January 2013, Cadence received a total of $14.6 million from the waiver of its option to purchase Incline Therapeutics, Inc., and the sale of the shares of Incline stock held by Cadence, resulting in a gain of $7.7 million.
  • On February 22, 2013, Cadence amended its existing supply agreement for OFIRMEV with Lawrence Laboratories, a member of the Bristol-Myers Squibb Company group of companies, extending the term of the Agreement through December 2018.
  • On March 6, 2013, Cadence and Baxter Healthcare Corporation announced the termination of the development and supply agreement for OFIRMEV between the two companies.
  • "In the first quarter we delivered strong sales growth, strengthened our balance sheet and solidified our supply chain for OFIRMEV. Our extended relationship with Lawrence Laboratories and agreement with Grifols to develop flexible plastic bags for OFIRMEV should enable us to meet increasing customer demand for OFIRMEV," said Ted Schroeder, President and CEO of Cadence.

    Financial ResultsCadence's net product revenue was $23.6 million for the three months ended March 31, 2013, which represents an increase of $15.6 million from the $8.0 million in net product revenue reported for the three months ended March 31, 2012. As of January 1, 2013, Cadence began to recognize revenue at the time that product is sold to a wholesaler, consistent with other companies with products at this stage of commercialization. Previously, revenue was recognized only when wholesalers sold the product to t
    '/>"/>

    SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
    2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
    3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
    4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
    5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
    6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
    7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
    8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
    9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
    10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
    11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... a meter in size, are around us every day. ... as in some innovative early cancer treatments, but they ... traffic emissions, cosmetics, sunscreen and electronics. , A team ... by Lan Yang, PhD, the Das Family Career Development ... collaborators at Tsinghua University in China have developed a ...
    (Date:9/2/2014)... September 02, 2014 Press attending the ... to take advantage of the people and events in ... below are available throughout the day. Additionally, we will ... POET and DSM representatives as well as representatives from ... is appreciated. , Please remember to RSVP to ...
    (Date:9/2/2014)... -- Technology Applications International Corporation (the "Company" or "NUUU")(OTC BB: ... Inc. has signed an additional exclusive licensing agreement with ... Johnson Space Center in Houston , ... Charles J. Scimeca , NUUU,s ... latest, exclusive agreement with NASA. In addition to our ...
    (Date:9/2/2014)... Sept. 2, 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Patent and Trademark Office (PTO) has issued a patent ... for weight loss. NB32 is a fixed-dose combination of ... U.S. Patent No. 8,815,889 claims methods for treating insulin ... patent expires in 2024. If NB32 is approved for ...
    Breaking Biology Technology:Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
    ... AC Immune SA, a leader,in Alzheimer,s disease drug development, ... Immune as Technology Pioneer 2009 for its,accomplishments as an ... a deep impact on business and society. , ... that it has reached significant clinical,milestones in the development ...
    ... A 60-year-old,prostate cancer patient from Montpellier has become ... RapidArc(TM) technology from Varian Medical Systems,(NYSE: ... intensity modulated radiotherapy,(IMRT). Each of his treatments at ... city took just 75 seconds, several times faster ...
    ... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it ... year 2009 on December 10, 2008 at 7:00 a.m. EST and ... at 11:30 a.m. EST on the same day. , ... results for the second quarter ended October 31, 2008 and will ...
    Cached Biology Technology:Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development 2Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 2Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 3Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results 2
    (Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
    (Date:9/2/2014)... the University of Warwick in the UK and the ... Journal Early Human Development , has found that ... birth and the use of mechanical ventilation are key ... Mathematic abilities are crucial for lifelong academic attainment. Impairments ... Earlier studies of children who are born very preterm ...
    (Date:9/2/2014)... the most ideal source of nutrition for infants ... in the evolution and civilizations of human beings. ... large number of bacterial species, including some opportunistic ... surprise to scientists and physicians. , Indeed, the ... the result of co-evolutionary and co-adaptive interactions between ...
    Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Mechanical ventilation a key indicator for pre-term children's math problems 2Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3
    ... on labor-intensive microscopic examination, using century-old cell-staining ... and may give false readings. , A ... Laboratories researcher Paul Gourley, has provided laboratory ... liver tumor cells at their earliest stages, ...
    ... Canadian Network for Vaccines and Immunotherapeutics, has announced,the ... well the thymus (an organ,located at the base ... a,functional abnormality of this organ in HIV-infected individuals. ... professor at,Université de Montréal, scientist at the CHUM ...
    ... used to synthesize plastic food containers has been ... of prostate cancer cell,potentially affecting the treatment efficacy ... published in the January 1 issue of Cancer,Research, ... to,exposure to the chemical BPA (bisophenol A), an ...
    Cached Biology News:Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells 2Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells 3Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells 2
    Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
    A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
    ... Neogens enzyme-linked immunosorbent assay (ELISA) ... as screening devices for the detection of ... The kits are intended for forensic use ... samples be confirmed by a quantitative method ...
    ... SUPERaseIn RNase Inhibitor (patent pending) is ... that noncovalently binds and inhibits the most ... B, C, 1 and T1. SUPERaseIn can ... contamination could be problematic. It is ideal ...
    Biology Products: